Polyethylene glycol 3350 (MiraLAX) and linaclotide (Linzess) are both medications used to treat constipation, but they belong to different drug classes and have distinct uses. MiraLAX is an osmotic laxative available over-the-counter, primarily used for occasional constipation by drawing water into the colon to soften stools. In contrast, Linzess is a prescription-only guanylate cyclase-C agonist, approved for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) in adults, as well as functional constipation in children aged 6 to 17. MiraLAX is taken as a powder mixed with a beverage once daily, while Linzess is a capsule taken on an empty stomach at least 30 minutes before a meal. MiraLAX is available in generic form, whereas Linzess is only available as a brand-name medication. Common side effects of MiraLAX include nausea, bloating, and gas, while Linzess can cause diarrhea, stomach pain, and gas. Linzess requires caution due to the risk of severe diarrhea and dehydration, especially in children under 2 years old, whereas MiraLAX is generally considered safe for short-term use with fewer severe side effects.